Contents

Highlights of This Issue 3089

SPECIAL FEATURES 3091

How to Train Your Biomarker 3091
Douglas Yee 3091
See article p. 3193

Inhibition of the PI3K Pathway: Hope We Can Believe in? 3094
Michiel S. van der Heijden and René Bernards

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway 3099
Laurence Zitvogel, Oliver Kepp, Laura Senovilla, Laurie Menger, Nathalie Chaput, and Guido Kroemer

Drugs That Target the Stemness Pathways 3105
Susan E. Bates

Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways 3106
Naoko Takebe and S. Percy Ivy

Cancer Stem Cells and Self-renewal 3113
Catherine Adell O’Brien, Antonija Kreso, and Catriona H.M. Jamieson

The Difficulty of Targeting Cancer Stem Cell Niches 3121
Mark A. LaBarge

Targeting Hedgehog—a Cancer Stem Cell Pathway 3130
Akil A. Merchant and William Matsui

Targeting Notch to Target Cancer Stem Cells 3141
Antonio Pannuti, Kimberly Foreman, Paola Rizzo, Clodia Osipo, Todd Golde, Barbara Osborne, and Lucio Miele

Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? 3153
Fumi Takahashi-Yanaga and Michael Kahn

Molecular Pathways

Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis 3163
Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashihara, Hisamichi Aizawa, Yuji Basaki, Michihiko Kuwano, Masayoshi Kage, Tetsuya Mitsudomi, and Mayumi Ono

Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2 3171
Gong Yang, Bin Chang, Fan Yang, Xiaoping Guo, Kathy Qi Cai, Xue (Sherry) Xiao, Huamin Wang, Subrata Sen, Mien-Chie Hung, Gordon B. Mills, Sandy Chang, Asha S. Maltuni, Imelda Mercado-Uribe, and Jinsong Liu

CCR Focus

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma 3182
Qing Liu, Lapo Alinari, Ching-Shih Chen, Fengting Yan, James T. Dalton, Rosa Lapalombella, Xiaoli Zhang, Rajeswaran Mani, Teresa Lin, John C. Byrd, Robert A. Baiocchi, and Natarajan Muthusamy

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development 3193
Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, MariaLeila Varella-Garcia, Christopher Korch, and S. Gail Eckhardt See commentary p. 3091
Molecular Imaging of N-linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer Therapy
Joseph N. Contessa, Mahaveer S. Bhojani, Hudson H. Freeze, Brian D. Ross, Alnawaz Rehemtulla, and Theodore S. Lawrence

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
María Victoria Mateos, Maria Teresa Cibeira, Paul G. Richardson, Felipe Prospert, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Ramón García-Sanz, Sonia Extremera, Sergio Syljergemajin, Claudia Corrado, Harald Singer, Constantine S. Mitsiades, Kenneth C. Anderson, Joan Bladé, and Jesús San Miguel

Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants
Barbara L. Andersen, Lisa M. Thornton, Charles L. Shapiro, William B. Farrar, Bethany L. Mundy, Hae-Chung Yang, and William E. Carson III

AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trail
Per-Uno Malmström, Angelica S.I. Loskog, Camilla A. Lindqvist, Sara M. Mangsbo, Moa Fransson, Alkwin Wanders, Truls Gårdmark, and Thomas H. Tötterman

Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients
ABOUT THE COVER

Early detection of gastric cancer requires risk assessment of premalignant conditions. The cover image shows a positive and negative representative immunostain of eight tissue markers (BRCA1, HSP90, EGFR, p73, STAT1, FHIT, p16INK4a and p53) and EBER-1 expression in tissue microarrays of early gastric cancer, nontumor adjacent mucosa, and chronic gastritis control cases, where p73 emerges and may have a potential role in the assessment of high-risk gastritis. Moreover, integration of these findings with histological features shows that overexpression of p73 is the most relevant finding. For further details, please see the article by Carrasco and colleagues on page 3253 of this issue.
Clinical Cancer Research

16 (12)

*Clin Cancer Res* 2010;16:3089-3295.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/16/12">http://clincancerres.aacrjournals.org/content/16/12</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>